Switch theme
Sign up to access all valuation multiples
Ortivus AB is a supplier of mobile solutions for modern emergency medical care. Its product portfolio includes MobiMed Smart and CoroNet.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ortivus has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Ortivus achieved revenue of $8.3M and an EBITDA of -$1.6M.
Ortivus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ortivus valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $8.7M | $8.3M | XXX | XXX | XXX |
| Gross Profit | $5.0M | $3.2M | XXX | XXX | XXX |
| Gross Margin | 58% | 38% | XXX | XXX | XXX |
| EBITDA | -$1.5M | -$1.6M | XXX | XXX | XXX |
| EBITDA Margin | -18% | -20% | XXX | XXX | XXX |
| Net Profit | $0.6M | -$1.9M | XXX | XXX | XXX |
| Net Margin | 7% | -23% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 13, 2025, Ortivus's stock price is SEK 1 (or $0).
Ortivus has current market cap of SEK 60.6M (or $6.2M), and EV of SEK 91.4M (or $9.4M).
See Ortivus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.4M | $6.2M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 13, 2025, Ortivus has market cap of $6.2M and EV of $9.4M.
Ortivus's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Ortivus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Ortivus and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $9.4M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | -5.8x | XXX | XXX | XXX |
| P/E | -2.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOrtivus's NTM/LTM revenue growth is n/a
Ortivus's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged n/a for the same period.
Over next 12 months, Ortivus's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Ortivus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Ortivus and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | N/A | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ortivus acquired XXX companies to date.
Last acquisition by Ortivus was XXXXXXXX, XXXXX XXXXX XXXXXX . Ortivus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ortivus founded? | Ortivus was founded in 1985. |
| Where is Ortivus headquartered? | Ortivus is headquartered in Sweden. |
| How many employees does Ortivus have? | As of today, Ortivus has 44 employees. |
| Who is the CEO of Ortivus? | Ortivus's CEO is Mr. Gustaf Nordenhok. |
| Is Ortivus publicy listed? | Yes, Ortivus is a public company listed on STO. |
| What is the stock symbol of Ortivus? | Ortivus trades under ORTI A ticker. |
| When did Ortivus go public? | Ortivus went public in 1995. |
| Who are competitors of Ortivus? | Similar companies to Ortivus include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Ortivus? | Ortivus's current market cap is $6.2M |
| What is the current revenue growth of Ortivus? | Ortivus revenue growth between 2023 and 2024 was -4%. |
| Is Ortivus profitable? | Yes, Ortivus is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
